Summary Risk of death and risk of recurrence in 108 potentially curable non-small-cell lung cancer patients were analysed with respect to TNM stage, histological type and carcinoembryonic antigen (CEA), CA125 antigen and squamous cell carcinoma antigen (SCC) levels in serum and cytosol. CA125 and CEA levels were closely related to outcome figures. Multivariate analyses indicated that TNM stage and histological type had the best predictive power, but serum and cytosolic CA125 and serum CEA contained additional, independent prognostic information. Predictive information drawn from serum and cytosolic levels proved mutually complementary. We conclude that CA125 and CEA complement TNM classification and histological type for the purpose of quantifying risk of death or recurrence.
The tumour -node-metastasis (TNM) classification system is the cornerstone for planning therapy options in patients with non-small-cell lung cancer (NSCLC) (Bains, 1991) . Such staging of tumour spread is the best available prognostic factor. However, its predictive power is limited. Differences may be seen between expected and actual outcome after curative resection among patients within the same TNM category of risk. Efforts are under way to confirm the possibility that long-term results or response to treatment may be partially based on biological characteristics inherent in tumour cells (Carney, 1991) . Methods for the description of biological tumour aggressiveness are rapidly expanding (Carney, 1991;  Lee and Hong, 1992) .
Owing to their low sensitivity and specificity, tumour markers have, until now, played a less important role in the diagnosis and management of NSCLC than has been the case with most other common cancers (Bergman et al., 1993; Strauss and Skarin, 1994; Jarvisalo et al., 1993) . Nevertheless, tumour markers might have a wide range of potential applications within the field of NSCLC as tools for description of tumour biological aggressiveness. Of these tumour markers, carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC) have been two of the most commonly used to date. Their sensitivity for detecting the primary tumour is low, ranging from 30% to 60% (Strauss and Skarin, 1994) depending upon histological type and TNM stage. Several authors have reported that serum CEA and serum SCC assay provide useful information for establishing preoperative prognosis in patients with localised and resectable disease (Gail et al., 1984; Sanchez et al., 1994) , guiding follow-up after surgical treatment (Diez et al., 1995) and monitoring response to chemotherapy in advanced disease (Shinkai et al., 1986; Spiridonis et al., 1995) . CA125 was initially described as an ovarian cancer-associated antigen, and has recently been assayed in NSCLC. In a previous study we reported that serum levels of CA 125 provide independent information on survival and tumour relapse in patients undergoing curative surgical treatment for NSCLC (Diez et al., 1994a) .
Analysis of tumour marker expression in NSCLC tumour tissue has not been reported as frequently. In a previous study we observed that cytosolic concentration of CEA, SCC and CA125 is a particular and distinctive characteristic of each histological type, something which could aid pathological classification (Picardo et al., 1994) . In addition, high CEA plus high CA125 content allows for identification of the large-cell carcinoma histological subtype (Picardo et al., 1994) . In our opinion, this kind of study could lead to a better understanding of the relationship between tumour marker and the biological features of the neoplasm.
This study aimed at assessing the ability of preoperative serum and cytosolic levels of CEA, CA125 and SCC antigens to provide information on the risk of death and recurrence in patients who had undergone curative surgical treatment for NSCLC. (World Health Organization, 1981) : 71 patients (65.7%) had squamous carcinoma, 29 (27%) adenocarcinoma and eight (7.3%), large-cell carcinoma. TNM staging (Mountain, 1986) Performance characteristics of immunometric assays depend upon the matrix of the sample. Commercially available kits are standardised for serum. As a prior step, we therefore had to validate the technique for the cytosol matrix. In order to ascertain the precision and accuracy of the assay, the first ten lung cancer samples were divided into four parts. All the steps of the analysis were repeated in these specimens separately. Variation coefficients of the technique for cytosols were 15% for CEA, 13% for CA125 and 16% for SCC. Intra-assay variation coefficients were 7% in the CEA assay, 6% in CA125 and 8% in SCC. Interassay variation coefficients were 10% in the CEA assay, 9% in CA125 and 11% in SCC.
Patients and methods

Statistical analysis
In the statistical analysis, median and interquartile distances were used as summary measures, owing to the asymmetric distribution of marker values. Survival and recurrence rates linked to tumour marker levels were studied using the Kaplan-Meier method, and differences between subgroups of patients were compared using Mantel's log-rank test. 
Results
Distribution of serum and cytosolic concentration of CEA, CA125 and SCC are depicted in Table I . Concentrations of all three markers were far higher in cytosol than in serum; likewise, the degree of dispersion was comparatively greater in the cytosol-based results.
Survival
The cumulative probability of survival over 36 month followup was 45%. In the univariate analysis this result was significantly related to histological type, TNM stage and CA125 levels in serum and cytosol (Table II) (Figures 1 and 2 ). Likewise, within adenocarcinoma, patients with high serum CEA levels exhibited significantly lower survival than those with low serum CEA (Figure 3 ). (Table IV) . High CA125 cytosolic and CEA serum levels were associated with a significantly lower probability of disease-free survival. (Sanchez et al., 1994; Spiridonis et al., 1995) , SCC showed no prognostic significance. We do not know the reason for the discrepancy. The results yielded by the multivariate analysis indicate that, for patients with serum CA125 and CEA under 10 U ml-1, and cytosolic CA125 under 100 U mg-', TNM stage and histological type are the most important predictive variables for both survival and recurrence. However, we have observed that the risk of recurrence or death increases in direct proportion to a rise in CA125 or CEA levels. Hence, where marker concentration rises, a point will be reached when the risk signalled by such markers may be greater than the risk indicated by a more advanced TNM stage or more aggressive histological type. For instance, in patients with CEA serum levels over 140 ng ml-', the negative influence of this marker is more important than the influence of TNM stage. This fact underscores the need to avoid dichotomous results (positive vs negative), at least in those cases in which such markers are employed for estimating the prognosis. It would seem more reasonable for these markers to be used as continuous variables, as this would enable any predictive information to be more efficiently exploited. Although a cutoff point is occasionally used to define a high-or low-risk group of patients, this approach tends to oversimplify and even distort the relationship between variables and outcome.
Systems for anatomical tumour staging, e.g. the TNM system, should continue as the standard patient classification reference system. Nevertheless, by using appropriate biological markers, groups differing in prognosis could be identified from among patients who had undergone curative resection. Improved staging and selection for immediate or delayed postoperative adjuvant treatment might thereby become possible (Murren et al., 1993) . The multivariate predictive model presented in this paper could be used to calculate postoperative risk on a patient-by-patient basis. Using the hazard ratios, one could estimate the risk of death or recurrence for any patient by multiplying the ratios for all factors present. An example of this would be a patient with stage Illa largecell carcinoma, having concentrations of cytosolic CA125 of 400 U mg-', serum CA125 of 40 U ml-1 and serum CEA of 40 ng ml -'. The calculated risk of such a patient dying of lung cancer would be nearly twice that of a patient with the same histological type and TNM stage but having the three markers in the lowest range.
The 5 year survival rate after curative resection of NSCLC ranges from 52% in patients with metastasis in hilar lymph nodes to 20% in patients with metastasis in mediastinal lymph nodes (Bains, 1991) . Adjuvant therapy following surgical resection and induction chemotherapy followed by surgery have been proposed as the best way of improving results after curative resection. At present, however, no clear survival-related advantage is to be gained by such measures (Shepherd, 1994) . Inadequate selection of patients might have conceivably contributed to inconclusive results. At some future date, a score derived from a multiple-regression approach, combining anatomical description of tumour spread with assessment of tumour aggressiveness, may well generate a patient-specific prognostic index (Fielding et al., 1992) . In our opinion, the possibility of individualising patient management and, especially, of tailoring adjuvant chemotherapy to TNM-based high-risk patients on the basis of CEA and CA125 levels, is an attractive prospect warranting further exploration. Patients at high risk for recurrence and death would receive adjuvant chemotherapy. Hypothetically, a treatment protocol could be constructed, with patients being stratified according to a given calculated risk vis-a-vis the overall population (Strauss et al., 1995) . However, in vitro and clinical studies would first have to investigate the ideal chemoradiation therapy for tumours expressing the marker.
The results of our study suggest that serum and cytosol furnish different and mutually complementary information. The likelihood ratios indicate that the partial models, in which serum and cytosol were considered separately, are significantly poorer predictors than the final combined model, in which serum and cytosol were considered jointly. This leads us to hypothesise that the relationship between marker levels in the two compartments is weak and may be determined by factors other than the rate of production (e.g. delivery into the bloodstream, necrosis, metabolism, hepatic and renal excretion, production at other sites).
For a biological parameter to be used as prognostic factor in clinical medicine, it is essential that the assay be cheap, simple, objective, comparable, reproducible and that the result be available in a short space of time to the doctor (Fielding et al., 1992) . In our opinion, serum and cytosolic quantification of CEA and CA125 clearly meets these requirements. From a theoretical standpoint, these factors offer some advantages over other predicitive parameters. Histological features (tumour grade, mitotic index, vascular invasion) and immunohistochemical evaluation of oncogeneencoded protein expression, furnish qualitative and semiquantitative information and are subject to a certain degree of interobserver variation. Direct genetic studies (DNA sequencing, polymerase chain reaction single-strand conformation polymorphism), although very useful for research purposes, are at present, unsuitable for application in daily clinical practice. However, no accurate determination of the practical importance of our findings can be made without first ascertaining the exact relationship between the predictive value of serum and cytosolic quantification of CEA and CA125 in tandem with other factors, for assessment of biological aggressiveness. Serum CA125, cytosolic CA125 and serum CEA are closely linked to outcome figures in NSCLC patients operated on with curative intent and provide prognostic information independent of TNM stage and histological type. Serum and cytosol furnish mutually complementary information. These biomarkers enhance current ability to quantify risk of recurrence or death on an individualised, patient-bypatient basis.
